Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis.

Erichsen L, Ghanjati F, Beermann A, Poyet C, Hermanns T, Schulz WA, Seifert HH, Wild PJ, Buser L, Kröning A, Braunstein S, Anlauf M, Jankowiak S, Hassan M, Bendhack ML, Bravo MA, Santourlidis S.

Sci Rep. 2018 Feb 22;8(1):3477. doi: 10.1038/s41598-018-21932-7.

PMID:
29472622
2.

Alternative transcription of a shorter, non-anti-angiogenic thrombospondin-2 variant in cancer-associated blood vessels.

Roudnicky F, Yoon SY, Poghosyan S, Schwager S, Poyet C, Vella G, Bachmann SB, Karaman S, Shin JW, Otto VI, Detmar M.

Oncogene. 2018 Feb 22. doi: 10.1038/s41388-018-0129-z. [Epub ahead of print]

PMID:
29467494
3.

The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation.

Umbehr MH, Bachmann LM, Poyet C, Hammerer P, Steurer J, Puhan MA, Frei A.

Health Qual Life Outcomes. 2018 Feb 20;16(1):36. doi: 10.1186/s12955-018-0859-1.

4.

Miniaturised percutaneous nephrolithotomy versus flexible ureteropyeloscopy: a systematic review and meta-analysis comparing clinical efficacy and safety profile.

Davis NF, Quinlan MR, Poyet C, Lawrentschuk N, Bolton DM, Webb D, Jack GS.

World J Urol. 2018 Feb 16. doi: 10.1007/s00345-018-2230-x. [Epub ahead of print] Review.

PMID:
29450733
5.

Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion.

Bhindi B, Jiang H, Poyet C, Hermanns T, Hamilton RJ, Li K, Toi A, Finelli A, Zlotta AR, van der Kwast TH, Evans A, Fleshner NE, Kulkarni GS.

Urol Oncol. 2017 Oct;35(10):604.e17-604.e24. doi: 10.1016/j.urolonc.2017.06.044. Epub 2017 Aug 7.

PMID:
28781111
6.

Prevalence and causes of abnormal PSA recovery.

Lautenbach N, Müntener M, Zanoni P, Saleh L, Saba K, Umbehr M, Velagapudi S, Hof D, Sulser T, Wild PJ, von Eckardstein A, Poyet C.

Clin Chem Lab Med. 2018 Jan 26;56(2):341-349. doi: 10.1515/cclm-2017-0246.

PMID:
28763294
7.

The Next Generation of Prostate Cancer Risk Calculators.

Hermanns T, Poyet C.

Eur Urol. 2017 Dec;72(6):897-898. doi: 10.1016/j.eururo.2017.05.006. Epub 2017 May 15. No abstract available.

PMID:
28522179
8.

Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.

Mortezavi A, Salemi S, Rupp NJ, Rüschoff JH, Hermanns T, Poyet C, Randazzo M, Simon HU, Moch H, Sulser T, Wild P, Eberli D.

Oncotarget. 2017 May 9;8(19):31765-31774. doi: 10.18632/oncotarget.15986.

9.

Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer.

Poyet C, Thomas L, Benoit TM, Delmo DA, Luberto L, Banzola I, Günthart MS, Sais G, Eberli D, Sulser T, Provenzano M.

Oncotarget. 2017 Mar 28;8(13):21871-21883. doi: 10.18632/oncotarget.15669.

10.

High expression of insulin receptor on tumour-associated blood vessels in invasive bladder cancer predicts poor overall and progression-free survival.

Roudnicky F, Dieterich LC, Poyet C, Buser L, Wild P, Tang D, Camenzind P, Ho CH, Otto VI, Detmar M.

J Pathol. 2017 Jun;242(2):193-205. doi: 10.1002/path.4892. Epub 2017 May 3.

PMID:
28295307
11.

A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients.

Zhong Q, Guo T, Rechsteiner M, Rüschoff JH, Rupp N, Fankhauser C, Saba K, Mortezavi A, Poyet C, Hermanns T, Zhu Y, Moch H, Aebersold R, Wild PJ.

Sci Data. 2017 Mar 14;4:170014. doi: 10.1038/sdata.2017.14.

12.

Detecting circulating tumor DNA in renal cancer: An open challenge.

Corrò C, Hejhal T, Poyet C, Sulser T, Hermanns T, Winder T, Prager G, Wild PJ, Frew I, Moch H, Rechsteiner M.

Exp Mol Pathol. 2017 Apr;102(2):255-261. doi: 10.1016/j.yexmp.2017.02.009. Epub 2017 Feb 23.

PMID:
28214514
13.

Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer.

Wettstein MS, Saba K, Umbehr MH, Murtola TJ, Fankhauser CD, Adank JP, Hofmann M, Sulser T, Hermanns T, Moch H, Wild P, Poyet C.

Prostate. 2017 Apr;77(5):549-556. doi: 10.1002/pros.23296. Epub 2017 Jan 17.

14.

Prostate cancer risk calculators: still much work ahead.

Poyet C, Hermanns T.

BJU Int. 2016 Nov;118(5):670-671. doi: 10.1111/bju.13497. No abstract available.

15.

External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC.

Poyet C, Wettstein MS, Lundon DJ, Bhindi B, Kulkarni GS, Saba K, Sulser T, Vickers AJ, Hermanns T.

J Urol. 2016 Nov;196(5):1402-1407. doi: 10.1016/j.juro.2016.05.081. Epub 2016 May 14.

16.

Prostate volume reduction following pure transurethral bipolar plasma vaporization and conventional transurethral resection of the prostate: a prospective investigation using transrectal 3D ultrasound volumetry.

Kranzbühler B, Gross O, Fankhauser CD, Wettstein MS, Grossmann NC, Hefermehl LJ, Zimmermann M, Müller A, Eberli D, Sulser T, Poyet C, Hermanns T.

World J Urol. 2017 Mar;35(3):429-435. doi: 10.1007/s00345-016-1876-5. Epub 2016 Jun 23.

17.

TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.

Groner AC, Cato L, de Tribolet-Hardy J, Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato ACB, Tschopp P, Gu L, Corsinotti A, Zhong Q, Fankhauser C, Fritz C, Poyet C, Wagner U, Guo T, Aebersold R, Garraway LA, Wild PJ, Theurillat JP, Brown M.

Cancer Cell. 2016 Jun 13;29(6):846-858. doi: 10.1016/j.ccell.2016.04.012. Epub 2016 May 26.

18.

Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity.

Zhong Q, Rüschoff JH, Guo T, Gabrani M, Schüffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C, Buhmann JM, Perner S, Poyet C, Blattner M, Soldini D, Moch H, Rubin MA, Noske A, Rüschoff J, Haffner MC, Jochum W, Wild PJ.

Sci Rep. 2016 Apr 7;6:24146. doi: 10.1038/srep24146.

19.

Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer.

Rupp NJ, Schüffler PJ, Zhong Q, Falkner F, Rechsteiner M, Rüschoff JH, Fankhauser C, Drach M, Largo R, Tremp M, Poyet C, Sulser T, Kristiansen G, Moch H, Buhmann J, Müntener M, Wild PJ.

J Pathol Inform. 2016 Jan 29;7:3. doi: 10.4103/2153-3539.175376. eCollection 2016.

20.

[Male Urinary Incontinence--a Taboo Issue].

Kozomara-Hocke M, Hermanns T, Poyet C.

Praxis (Bern 1994). 2016 Mar 2;105(5):269-77. doi: 10.1024/1661-8157/a002297. Review. German.

21.

Clinical impact of prostate biopsy undergrading in an academic and community setting.

Mortezavi A, Keller EX, Poyet C, Hermanns T, Saba K, Randazzo M, Fankhauser CD, Wild PJ, Moch H, Sulser T, Eberli D.

World J Urol. 2016 Oct;34(10):1481-90. doi: 10.1007/s00345-016-1788-4. Epub 2016 Mar 1.

22.

IDLN-MSP: Idiolocal normalization of real-time methylation-specific PCR for genetic imbalanced DNA specimens.

Santourlidis S, Ghanjati F, Beermann A, Hermanns T, Poyet C.

Biotechniques. 2016 Feb 1;60(2):84-7. doi: 10.2144/000114379. eCollection 2016 Feb.

23.

Absorption of irrigation fluid during XPS™ GreenLight laser vaporization of the prostate: results from a prospective breath ethanol monitoring study.

Wettstein MS, Poyet C, Grossmann NC, Fankhauser CD, Keller EX, Kozomara M, Meyer S, Sulser T, Müller A, Hermanns T.

World J Urol. 2016 Sep;34(9):1261-7. doi: 10.1007/s00345-016-1766-x. Epub 2016 Jan 16.

PMID:
26780733
24.

Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer.

Poyet C, Hermanns T, Zhong Q, Drescher E, Eberli D, Burger M, Hofstaedter F, Hartmann A, Stöhr R, Zwarthoff EC, Sulser T, Wild PJ.

Oncol Lett. 2015 Nov;10(5):2753-2760. Epub 2015 Sep 9.

25.

Long-Term Oncologic Outcome of an Initial Series of Laparoscopic Radical Prostatectomy for Clinically Localized Prostate Cancer After a Median Follow-up of 10 Years.

Mortezavi A, Sulser T, Robbiani J, Drescher E, Disteldorf D, Eberli D, Poyet C, Baumgartner MK, Seifert HH, Hermanns T.

Clin Genitourin Cancer. 2016 Aug;14(4):290-7. doi: 10.1016/j.clgc.2015.11.006. Epub 2015 Nov 17.

PMID:
26710661
26.

Influence of Varying Assessment Parameters on the Diagnostic Accuracy of Magnetic Resonance Imaging in the Local Staging of Prostate Cancer.

Umbehr MH, Lüscher M, Hunziker R, Falkner F, Wild PJ, Poyet C, Seifert B, Müntener M.

Urol Int. 2016;96(3):309-14. doi: 10.1159/000441733. Epub 2015 Dec 16.

27.

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer.

Wettstein MS, Buser L, Hermanns T, Roudnicky F, Eberli D, Baumeister P, Sulser T, Wild P, Poyet C.

Dis Markers. 2015;2015:785461. doi: 10.1155/2015/785461. Epub 2015 Oct 12.

28.

Predictive value of low tube voltage and dual-energy CT for successful shock wave lithotripsy: an in vitro study.

Largo R, Stolzmann P, Fankhauser CD, Poyet C, Wolfsgruber P, Sulser T, Alkadhi H, Winklhofer S.

Urolithiasis. 2016 Jun;44(3):271-6. doi: 10.1007/s00240-015-0824-y. Epub 2015 Sep 21.

PMID:
26391614
29.

Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.

Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Wettstein MS, Largo R, Wild P, Sulser T, Hermanns T.

BJU Int. 2016 Mar;117(3):401-8. doi: 10.1111/bju.13314. Epub 2015 Oct 5.

30.

Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.

Poyet C, Buser L, Roudnicky F, Detmar M, Hermanns T, Mannhard D, Höhn A, Rüschoff J, Zhong Q, Sulser T, Moch H, Wild PJ.

J Clin Pathol. 2015 Oct;68(10):819-24. doi: 10.1136/jclinpath-2015-202898. Epub 2015 Aug 6.

31.

High VEGF-D and Low MMP-2 Serum Levels Predict Nodal-Positive Disease in Invasive Bladder Cancer.

Benoit T, Keller EX, Wolfsgruber P, Hermanns T, Günthart M, Banzola I, Sulser T, Provenzano M, Poyet C.

Med Sci Monit. 2015 Aug 4;21:2266-74. doi: 10.12659/MSM.894383.

32.

Long-term Adverse Effects of Extracorporeal Shock-wave Lithotripsy for Nephrolithiasis and Ureterolithiasis: A Systematic Review.

Fankhauser CD, Kranzbühler B, Poyet C, Hermanns T, Sulser T, Steurer J.

Urology. 2015 May;85(5):991-1006. doi: 10.1016/j.urology.2014.12.014. Review.

33.

Antibody response to BK polyomavirus as a prognostic biomarker and potential therapeutic target in prostate cancer.

Keller XE, Kardas P, Acevedo C, Sais G, Poyet C, Banzola I, Mortezavi A, Seifert B, Sulser T, Hirsch HH, Provenzano M.

Oncotarget. 2015 Mar 20;6(8):6459-69.

34.

pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.

Ruf M, Mittmann C, Nowicka AM, Hartmann A, Hermanns T, Poyet C, van den Broek M, Sulser T, Moch H, Schraml P.

Clin Cancer Res. 2015 Feb 15;21(4):889-98. doi: 10.1158/1078-0432.CCR-14-1425.

35.

Acute abdominal pain accompanied by high creatinine in a female patient with schizophrenia.

Mauerhofer E, Lüscher M, Poyet C, Saba K, Andreisek G, Sulser T, Mortezavi A.

Urology. 2015 Mar;85(3):495-8. doi: 10.1016/j.urology.2014.10.034. Epub 2014 Nov 4. No abstract available.

PMID:
25543890
36.

Unreserved application of epigenetic methods to define differences of DNA methylation between urinary cellular and cell-free DNA.

Ghanjati F, Beermann A, Hermanns T, Poyet C, Araúzo-Bravo MJ, Seifert HH, Schmidtpeter M, Goering W, Sorg R, Wernet P, Santourlidis S.

Cancer Biomark. 2014;14(5):295-302. doi: 10.3233/CBM-140407.

PMID:
25171471
37.

Absorption of irrigation fluid occurs frequently during high power 532 nm laser vaporization of the prostate.

Hermanns T, Grossmann NC, Wettstein MS, Fankhauser CD, Capol JC, Poyet C, Hefermehl LJ, Zimmermann M, Sulser T, Müller A.

J Urol. 2015 Jan;193(1):211-6. doi: 10.1016/j.juro.2014.07.117. Epub 2014 Aug 7.

38.

Bilaterally positive biopsy cores are associated with non-organ-confined disease in prostate cancer patients eligible for active surveillance.

Umbehr MH, Largo RA, Gfeller S, Tremp M, Poyet C, Paul M, Sulser T, Müntener M.

Urol Int. 2014;93(2):176-81. doi: 10.1159/000357121. Epub 2014 Mar 15.

39.

Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer.

Poyet C, Jentsch B, Hermanns T, Schweckendiek D, Seifert HH, Schmidtpeter M, Sulser T, Moch H, Wild PJ, Kristiansen G.

BMC Clin Pathol. 2014 Mar 13;14(1):10. doi: 10.1186/1472-6890-14-10.

40.

Ablative efficiency of 532-nm laser vaporization compared to transurethral resection of the prostate: results from a prospective three-dimensional ultrasound volumetry study.

Hermanns T, Gross O, Kranzbühler B, Hefermehl LJ, Poyet C, Müller A, Yap SA, Michel MS, Eberli D, Müntener M, Zimmermann M, Sulser T, Seifert HH.

World J Urol. 2014 Oct;32(5):1267-74. doi: 10.1007/s00345-013-1203-3. Epub 2013 Oct 31.

PMID:
24173627
41.

Lateral temperature spread of monopolar, bipolar and ultrasonic instruments for robot-assisted laparoscopic surgery.

Hefermehl LJ, Largo RA, Hermanns T, Poyet C, Sulser T, Eberli D.

BJU Int. 2014 Aug;114(2):245-52. doi: 10.1111/bju.12498. Epub 2014 Jan 22.

42.

Pure bipolar plasma vaporization of the prostate: the Zürich experience.

Kranzbühler B, Wettstein MS, Fankhauser CD, Grossmann NC, Gross O, Poyet C, Largo R, Fischer B, Zimmermann M, Sulser T, Müller A, Hermanns T.

J Endourol. 2013 Oct;27(10):1261-6. doi: 10.1089/end.2013.0335. Epub 2013 Aug 21.

43.

Therapy-resistant nephrolithiasis following renal artery coil embolization.

Poyet C, Grubhofer F, Zimmermann M, Sulser T, Hermanns T.

BMC Urol. 2013 Jun 10;13:29. doi: 10.1186/1471-2490-13-29.

44.

Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis.

Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, Rogler A, Stöhr R, Hartmann A, Provenzano M, Otto VI, Detmar M.

Cancer Res. 2013 Feb 1;73(3):1097-106. doi: 10.1158/0008-5472.CAN-12-1855. Epub 2012 Dec 14.

45.

Artificial prostate-specific antigen persistence after radical prostatectomy.

Poyet C, Hof D, Sulser T, Müntener M.

J Clin Oncol. 2012 Feb 10;30(5):e62-3. doi: 10.1200/JCO.2011.38.2788. Epub 2011 Dec 27. No abstract available.

PMID:
22203757
46.

MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal.

Fedier A, Poyet C, Perucchini D, Boulikas T, Fink D.

Anticancer Drugs. 2006 Mar;17(3):315-23.

PMID:
16520660
47.

Supplemental Content

Support Center